XFOR - X4 Pharmaceuticals to Host Virtual Investor Event on June 27 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia | Benzinga
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the event, click here.
The event will focus on new interim results from an ongoing Phase 2 clinical trial exploring the use of mavorixafor as a once-daily oral treatment in patients with chronic neutropenia (CN). The data to be presented will include hematological results from at least 15 study participants treated with either mavorixafor monotherapy or mavorixafor in combination with stable doses of injectable granulocyte colony-stimulating factor (G-CSF). Physician expert commentary on the clinical results and the high unmet need in CN will also be included as part of the event.
As previously communicated, the company plans to initiate a global, pivotal Phase 3 clinical trial in the current quarter that aims to evaluate the efficacy, safety, and tolerability of oral once-daily mavorixafor (with or without G-CSF) in people with congenital or acquired primary autoimmune and idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections.
A live question and answer session will follow the formal presentation.
About Chronic Neutropenia and Mavorixafor
Chronic neutropenic disorders are rare blood conditions lasting more than three months, persistently or intermittently, and characterized by increased risk of infections and reduced quality of life due to persistent, abnormally low levels of neutrophils circulating in the blood. Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells; downregulation of the CXCR4 receptor by G-CSF ...